

FORM 7

MONTHLY PROGRESS REPORT

Name of Listed Issuer: **BioMark Diagnostics Inc.** (the "Issuer").

Trading Symbol: **BUX**

Number of Outstanding Listed Securities: **105,090,213**

Date: **April 4th, 2026**

This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer's obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by Exchange Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date, and the posting date on the Exchange website.

This report is intended to keep investors and the market informed of the Issuer's ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are "material information" as defined in the Policies. The discussion in this report must be factual, balanced, and non-promotional.

General Instructions

- (a) Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered, nor should question be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title of each item must precede the answer.
- (b) The term "Issuer" includes the Issuer and any of its subsidiaries.
- (c) Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

Report on Business

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

The Issuer continued its business of developing and accelerating the commercialization of its proprietary, non-invasive, and accurate cancer diagnostic solutions, which can help detect, monitor, and assess cancer treatment early, accurately, and cost-effectively. The Company has developed its annual roadmap and continues to hold regular management meetings to discuss all aspects of the Company's business plan. It executes action items that result from these meetings.

Management's primary areas of focus continue to include:

- **Accelerating commercialization efforts of its lab-developed test (LDT) for early lung cancer detection following promising interim retrospective data presented at various oncology conferences across N. America and Europe.**
- **These results were statistically significant and continued to generate interest from leading institutions in the US, France, Germany and South America, which the company intends to pursue post-launching its assay initially in Canada following certification of its Quebec-based lab and data readout on its lung cancer clinical studies.**
- **Complete data analytics on the large-scale early lung cancer multimodal study (5,400 patients) across 7 hospitals based in Quebec after the successful completion of plasma samples and analysis using BioMark's metabolomics assay. Preliminary results from the retrospective, cancer-confirmed patient cohort, which includes an expanded non-cancer control group, have been analyzed, and the robust results met all assay performance metrics—high sensitivity and specificity. The company is discussing with key opinion leaders at the Institut universitaire de cardiologie et de pneumologie de Québec (IUCPQ) on where and when to publish the data. Additional data on the prospective lung cancer screening cohort continues to be collected in 2026 as detailed in the clinical design. Pending the outcome of the results, the company intends to present it at a major cancer symposium.**

- **Seek deeper collaborations with several high-profile USA medical institutions and introduce the company to insurance companies (payers), regulatory experts, advocacy groups, and biopharma partners as its early lung cancer LDT commercialization efforts gather momentum. The US market is strategic due to its large addressable lung cancer screening market for at-risk populations (estimated at over 16 million annually). The market remains mostly untapped as there's only a 5-6% penetration of image-based screening for the population at risk of developing lung cancer. In addition, the federal government is encouraging expanded accessibility for lung cancer screening initiatives across different states, especially for rural communities that are resource - constrained.**
 - **Continue to seek and secure the necessary funding to unlock the full potential of its diagnostic platform. The Company will continue to target non-dilutive funding opportunities from Canadian, European, and U.S. agencies and foundations to support key initiatives, including:**
 - **Optimizing our lab operations**
 - **Achieving clinical lab certification**
 - **Gathering additional real-world evidence**
 - **Embedding more AI and ML capabilities**
 - **Driving U.S. expansion and payor endorsement**
 - **Fueling business development**
 - **Conducting clinical studies to extend the platform to additional cancers and define its role in treatment response assessment**
 - **Filing patents to protect discoveries and strategically expand patent estate**
2. Provide a general overview and discussion of the activities of management.
- **Despite persistent ongoing geopolitical tensions and resulting global economic challenges, the company is strategically positioned to navigate these hurdles and capitalize on the significant opportunities within the oncology molecular diagnostics sector. Our core expertise in metabolomics and AI-driven biomarker discovery directly addresses the need for earlier (stage shifting), accessible, and more precise cancer detection. While navigating a cautious investment landscape and a rapidly evolving technology environment with a scarce talent market, the Company has proactively implemented agile strategies and resilient operational and financial systems to counteract these headwinds. Furthermore, recognizing the transformative power of technology, the**

Company is strategically building a robust AI infrastructure through key collaborations, aiming to leverage advanced analytics to enrich assay results and enhance its cancer diagnostics capabilities. The company is committed to continuous innovation and disciplined execution to realize the full potential of these opportunities for our stakeholders.

- **BioMark operates within a challenging economic environment that significantly impacts small-cap diagnostic companies. The funding landscape shows recovery with continued selectivity for investment. This environment particularly challenges emerging diagnostic companies like BioMark, as investors continue to prioritize clinical-stage companies with proven concepts. Investor caution and a skilled labor shortage in bioinformatics are impacting the industry. Financing timelines are extended, making fundraising particularly challenging for small-cap diagnostic companies.**
- **BioMark submitted an application titled Accessible Early Lung Cancer Detection: A Home-Based AI-Enhanced Blood Test for Remote and At-Risk Population, to the Canadian Thoracic Society (CTS) Beaver Den Innovation Competition on January 25, 2026. This initiative aims to democratize access to early lung cancer detection, improve participation, advance health equity, and increase early intervention rates. By combining convenient home sampling, metabolomic precision leveraging AI, BioMark aims to transform how—and where—lung cancer is detected. BioMark has been selected as one of the four finalists and invited to present its proposal during The Beaver Den session at the Canadian Respiratory Conference (CRC) 2026, taking place April 16 –18, 2026, at the Calgary TELUS Convention Centre in Calgary, AB. Any positive outcome will be subsequently disclosed.**
- **On March 12, 2026, BioMark was invited for a special forum with the government of Tanzania. The presentation was well received by the health officials in Tanzania. In addition, BioMark completed a submission for a call called The Canada Fund for Local Initiatives (CFLI). It funds small, high-impact projects led by local civil society organizations, education institutions, and other significant partners that understand local needs and that are best equipped to address them. The Canadian federal govt is building its international business strategically and Africa is now considered an important market by Global Trade Canada, which**

has a mandate to seek and expand Canadian-led business to new international markets. Any positive outcome will be reported in due course.

- On March 13, 2026, BioMark was invited to present its lung cancer metabolic assay potential utility for parties/communities at high risk of radon exposure during the Symposium on Radon and Radiation Protection in Saskatoon from May 27 to May 31, 2026. The abstract for the Symposium has been submitted. More details will be reported in due course. The 2026 Symposium on Radon and Radiation Protection is a collaborative effort between the Canadian Association of Radon Scientists and Technologists (CARST) and the Canadian Radiation Protection Association (CRPA). This partnership brings together the expertise and vast networks of two leading organizations dedicated to advancing radiation safety and promoting best practices in the field. The goal is to significantly impact the radon and radiation protection landscape in Canada and beyond.
- Following BioMark's October 7, 2025, announcement regarding its participation in the landmark HANSE lung cancer screening trial in Germany, significant progress has been achieved. By the end of March 2026, over 6000 participants had enrolled in the trial, and their samples had been successfully analyzed at BioMark's laboratory in Quebec City. Information and data are being shared confidentially at several important events, such as the lung cancer nodule conference in Germany. Overall, the HANSE trial continues to advance as planned, marking a key milestone in BioMark's global clinical and market validation efforts. Regular meetings continue to be held with HANSE group tumor board members. The project wrap-up is scheduled for the end of June/July 2026.
- BioMark's strategic collaboration with Harrisburg University under the leadership of Dr. Maria Vaida, Assistant Professor of Data Science, along with her Ph.D. student team, created a semantic embedded deep learning framework that provides an additive predictive signal across linear, kernel based, tree based, and neural network models from blood plasma using metabolites that significantly enhances biologic assay performance and diagnostic capabilities. Several papers are in the pipeline for the submissions to relevant and important journals

throughout the year. The team has selected an appropriate high-impact journal and will be submitting one paper for publication in April 2026.

- The Company has been approached by multiple international institutions and investment brokers regarding potential partnerships and licensing opportunities aligned with its commercialization strategy. While discussions remain at a preliminary stage, any material developments will be disclosed in future updates. In addition, BioMark received interest from two U.S. states exploring potential business expansion opportunities. Any substantive progress in these discussions will be announced in subsequent monthly reports.
- BioMark continues to entertain discussions with various financial institutions, accredited individual investors, and government agencies to secure non-dilutive funding, favourable loans, and equity investments to accelerate the commercialization of its early lung cancer liquid biopsy franchise, to advance its expansion strategy in the USA and internationally as well as for general corporate purposes.

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

Not applicable.

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

Not applicable.

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements, etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

Not applicable.

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

Not applicable.

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from, or the disposition was to a Related Person of the Issuer and provide details of the relationship.

Not applicable.

8. Describe the acquisition of new customers or loss of customers.

Not applicable.

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists, and trademarks.

The Issuer continues to file trademarks and patents in specific jurisdictions for all its patents. Review of the filings and opinions from patent offices are being reviewed as needed.

10. Report on any employee hiring, terminations or lay-offs with details of the anticipated length of lay-offs.

Not applicable.

11. Report on any labour disputes and resolutions of those disputes if applicable.

Not applicable.

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

Not applicable.

13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

Not applicable.

14. Provide details of any securities issued and options or warrants granted.

Not applicable.

15. Provide details of any loans to or by Related Persons.

Not applicable.

16. Provide details of any changes in directors, officers, or committee members.

Not applicable.

17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

The trends and risks that are likely to impact the Issuer are discussed in the Form 51-102F1 Management's Discussion & Analysis Annual Report for the Year Ended March 31, 2025.

Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there where is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated April 4th, 2026

Rashid Ahmed Maula Bux
Name of Director or Senior Officer

"Rashid Ahmed Maula Bux"
Signature

President & CEO
Official Capacity

Issuer Details Name of Issuer BioMark Diagnostics Inc.	For Month End March 31, 2026	Date of Report YY/MM/DD 2026/04/04
Issuer Address 145 - 10451 Shellbridge Way		
City/Province/Postal Code Richmond, BC, V6X 2W8	Issuer Fax No. N/A	Issuer Telephone No. (604) 370-0779
Contact Name Rashid Ahmed Bux	Contact Position CEO	Contact Telephone No. (604) 370-0779
Contact Email Address info@biomarkdiagnostics.com	Web Site Address www.biomarkdiagnostics.com	

FORM 7 – MONTHLY PROGRESS REPORT